The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Lipid lowering with PCSK9 inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Cited by
Drug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders
Smoller, J. W. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.266 · Cited by 480
Ference, B. A., Majeed, F., Penumetcha, R., Flack, J. M., & Brook, R. D. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.020 · Cited by 407
“This analysis not only included NPC1L1 and HMGCR polymorphisms, but also both common and rare polymorphisms in the PCSK9 gene (which encodes the target of a new class of LDL-Clowering therapy under active investigation) (23).”
BackgroundGanz, P., Heidecker, B., Hveem, K., Jonasson, C., Kato, S., Segal, M. R., Sterling, D. G., & Williams, S. A. (2016) · JAMA · doi:10.1001/jama.2016.5951 · Cited by 364
PCSK9 inhibitors: A new era of lipid lowering therapy
Chaudhary, R., Garg, J., Shah, N., & Sumner, A. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i2.76 · Cited by 299
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Zhang, X.-L., Zhu, Q.-Q., Zhu, L., Chen, J.-Z., Chen, Q.-H., Li, G.-N., Xie, J., Kang, L.-N., & Xu, B. (2015) · BMC Medicine · doi:10.1186/s12916-015-0358-8 · Cited by 260
“intensive LDL-C lowering because of extremely high baseline LDL-C levels, or patients with very high risk of CVD events need more intensive lowering therapy [3].”
BackgroundStatin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Bergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
Yeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
Shimada, Y. J., & Cannon, C. P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv174 · Cited by 98
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89
“The evidence from trials in these patients indicates that evolocumab might be an efficacious and tolerable option for them, a conclusion also drawn by Dadu and Ballantyne [78] in their review of lipid lowering with PCSK9 inhibitors.”
BackgroundBarbeira, A. N., Dickinson, S. P., Bonazzola, R., Zheng, J., Wheeler, H. E., Torres, J. M., Torstenson, E. S., Shah, K. P., Garcia, T., Edwards, T. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03621-1 · Cited by 69
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
The life cycle of the low-density lipoprotein receptor: insights from cellular and in-vivo studies
Wijers, M., Kuivenhoven, J. A., & van de Sluis, B. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000157 · Cited by 55
Strategies for derisking translational processes for biomedical technologies
Abou-El-Enein, M., Duda, G. N., Gruskin, E. A., & Grainger, D. W. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.007 · Cited by 36
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
Sobati, S., Shakouri, A., Edalati, M., Mohammadnejad, D., Parvan, R., Masoumi, J., & Abdolalizadeh, J. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.062 · Cited by 33
Du, Y., Xi, M., Li, Y., Zheng, R., Ding, X., Li, X., Zhang, X., Wang, L., Xing, J., & Hong, B. (2023) · Phytomedicine · doi:10.1016/j.phymed.2022.154577 · Cited by 21
Arunsak, B., Pratchayasakul, W., Amput, P., Chattipakorn, K., Tosukhowong, T., Kerdphoo, S., Jaiwongkum, T., Thonusin, C., Palee, S., Chattipakorn, N., et al. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108470 · Cited by 19
Rodríguez‐Pérez, C., Ramprasath, V. R., Pu, S., Sabra, A., Quirantes‐Piné, R., Segura‐Carretero, A., & Jones, P. J. (2016) · Lipids · doi:10.1007/s11745-015-4099-4 · Cited by 16
Human genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Hernandez Torres, L. D., Rezende, F., Peschke, E., Will, O., Hövener, J.-B., Spiecker, F., Özorhan, Ü., Lampe, J., Stölting, I., Aherrahrou, Z., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1338458 · Cited by 8
“PCSK9 inhibition is, therefore, a rational therapeutic target in treating patients suffering from atherosclerosis (9).”
Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
Nejabat, M., Hadizadeh, F., Almahmeed, W., & Sahebkar, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104316 · Cited by 7
Metadata
- Authors
- Dadu, R. T., & Ballantyne, C. M.
- Venue
- Nature Reviews Cardiology
- Published
- 2014-06-24
- Volume
- 11
- Issue
- 10
- Pages
- 563-575
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W2016195709
- Cited by
- 237
- References
- 29
- FWCI
- 7.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.